175 related articles for article (PubMed ID: 37305581)
1. Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins.
Steinlein S; Essmann F; Ghilardi AF; Horn H; Schüler J; Hausser A; Sun L; Ott G; Kalla C
Front Oncol; 2023; 13():1190988. PubMed ID: 37305581
[TBL] [Abstract][Full Text] [Related]
2. Novel indolyl-chalcones target stathmin to induce cancer cell death.
Wegiel B; Wang Y; Li M; Jernigan F; Sun L
Cell Cycle; 2016 May; 15(9):1288-94. PubMed ID: 26986925
[TBL] [Abstract][Full Text] [Related]
3. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
[TBL] [Abstract][Full Text] [Related]
5. Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
Birnie KA; Yip YY; Ng DC; Kirschner MB; Reid G; Prêle CM; Musk AW; Lee YC; Thompson PJ; Mutsaers SE; Badrian B
Mol Cancer Res; 2015 Jul; 13(7):1106-18. PubMed ID: 25824152
[TBL] [Abstract][Full Text] [Related]
6. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
8. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
10. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
11. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
13. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
15. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
Denis I; Cellerin L; Gregoire M; Blanquart C
Oncotarget; 2014 Nov; 5(22):11641-52. PubMed ID: 25361002
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior.
Mathilakathu A; Wessolly M; Mairinger E; Uebner H; Kreidt D; Brcic L; Steinborn J; Greimelmaier K; Wohlschlaeger J; Schmid KW; Mairinger FD; Borchert S
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328699
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
Kang Y; Ding M; Tian G; Guo H; Wan Y; Yao Z; Li B; Lin D
Oncol Rep; 2013 Jul; 30(1):313-9. PubMed ID: 23624653
[TBL] [Abstract][Full Text] [Related]
20. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
